Management of hepatitis C virus (HCV) infection in drug substitution programs

Swiss Medical Weekly

Volumn 141, Issue MAY, 2011, Pages

  Witteck, Andrea ^a   Schmid, Patrick ^a   Hensel Koch, Katharina ^b   Thurnheer, Maria C ^c   Bruggmann, Philip ^d   Vernazza, Pietro ^a   Negro, F ^e   Hadengue, A ^f   Kaiser, L ^f   Rubbia Brandt, L ^f   Moradpour, D ^f   Burgisser, P ^g   Francioli, P ^g,h   Estoppey Younes, S ^g   Schoni Affolter, F ^g   Rickenbach, M ^g   Martinetti, G ^l   Cerny, A ^l   Masserey Spicher, V ^l   Gorgievski, M ^l   Dufour, J F ^l   Hirsch, H ^l   Heim, H ^l   Helbling, B ^l   Mullhaupt B ^l   Regenass, S ^g   Malinverni, R ^l   Meyenberger, C ^l   Borovicka, J ^l   Dollenmaier, G ^l   Cathomas, G ^l   Battegay, M ^h   Bernasconi, E ^h   Boni J ^h   Bucher, H C ^h   Burgisser P ^h   Calmy, A ^h   Cattacin, S ^h   Cavassini, M ^h   Dubs, R ^h   Egger, M ^h   Elzi, L ^h   Fischer, M ^h   Flepp, M ^h   Fontana, A ^h   Furrer, H ⁱ   Fux, C A ^j   Gunthard H F ^j   Hirsch, H H ^g   Hirschel, B ^g   Hosli I ^g   Kahlert, C ^g   Karrer, U ^g   Kind, C ^g   Klimkait, T ^g   Ledergerber, B ^g   Muller N ^g   Nadal, D ^g   Paccaud, F ^g   Pantaleo, G ^g   Rauch, A ^g   Rudin, C ^k   Schultze, D ^l   Schoni Affolter F ^l   Schupbach J ^l   Speck, R ^l   De Tejada, B M ^l   Taffe P ^l   Telenti, A ^l   Trkola, A ^l   Weber, R ^l   Yerly, S ^l   more..

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b Stiftung Suchthilfe   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d Die Arbeitsgemeinschaft fur risikoarmen Umgang mit Drogen   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f Scientific Committee   (Switzerland)

^g Data Center   (Switzerland)

^h Swiss HIV Cohort Study   (Switzerland)

ⁱ Clinical and Laboratory Committee   (Switzerland)

^j Scientific Board   (Switzerland)

^k Mother and Child Substudy   (Switzerland)

^l NONE

more..

Author keywords

Delay of diagnosis and treatment; Drug substitution program; Genotype distribution; HCV treatment success; HCV treatment uptake; Heroin; HIV HCV co infection; Methadone; Potential treatment barriers; Spontaneous clearance

Indexed keywords

ABACAVIR; DIAMORPHINE; EMTRICITABINE; LAMIVUDINE; METHADONE; TENOFOVIR; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DELAYED DIAGNOSIS; DRUG SUBSTITUTION; ECHOGRAPHY; ENDOSCOPY; FEMALE; GASTROSCOPY; GENOTYPE; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER CLEARANCE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIROLOGY; ADDICTION; BLOOD; CROSS-SECTIONAL STUDY; DRUG DEPENDENCE TREATMENT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; STATISTICS; SWITZERLAND; TIME;

ADULT; ANTIVIRAL AGENTS; CROSS-SECTIONAL STUDIES; DELAYED DIAGNOSIS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; RNA, VIRAL; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE-RELATED DISORDERS; SWITZERLAND; TIME FACTORS; YOUNG ADULT;

EID: 79958195213     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2011.13193     Document Type: Article

References (48)

1. Broers B, Helbling B, François A, Schmid P, Chuard Ch, Hadengue A, Negro F, for the Swiss Association for the Study of the Liver (SASL 18). Barriers to interferon-α therapy are higher in intravenous drug users than in other patients with acute hepatitis C. Journal of Hepatology. 2005;42:323-8. (Pubitemid 40254245)
2. Bruggmann P, Broers B, Meili D. Hepatitis C-Therapie bei Patienten unter Opioidsusbstitution. Empfehlungen der Schweizerischen Gesellschaft für Suchtmedizin (SSMA). Schweiz Med Forum. 2007;7:916-9.
3. Bruggmann P, Kormann A, Meili D. Heroin substitution: an exception or an expanded feasibility for providing hepatitis treatment to drug users? Hot Topics in Viral Hepatitis. 2009;13:27-33.
4. Belfiori B, Ciliegi P, Chiodera A, Bacosi D, Tosti A, Baldelli F, et al. Peginterferon plus ribavirin for chronic hepatitic C in opiate addicts on methadone/buprenorphine maintenance therapy. Dig Liver Dis. 2009;41(4):303-7.
5. Grebely J, de Vlaming S, Duncan F, Vilioen M, Conway B. Current approaches to HCV infection in current and former injection drug users. J Addict Dis. 2008;27(2):25-35.
6. Bruggmann P, Falcato L, Dober S, Helbling B, Keiser O, Negro F, et al. Swiss Hepatitis C Cohort Study. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepat. 2008;15(10):747-52.
7. Prasad L, Spicher VM, Zwahlen M, Rickenbach M, Helbling B, Negro F and Swiss Hepatitis C Cohort Study Group. Cohort Profile: The Swiss Hepatitis C Cohort Study (SCCS). Int J Epidemiol. 2007;36:731-7.
8. Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health. 2008;33(3):126-33.
9. Martin-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, et al. Incidence and predictors of severe liver fibrosis in HIV infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis. 2004;38:128-33. (Pubitemid 38045883)
10. Martinez-Sierra C, Arizcorreta A, Diaz F, Roldan R, Martin-Herrera L, Perez-Guzman L, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis. 2003;36:491-8. (Pubitemid 36241318)
11. Marin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Gonzalez-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses. 2001;17:1467-72.
12. Bica I, McGovern B, Dhar R, McGowan K, Scheib R, Snydman D. Increasing mortality due to end-stage liver disease in patients with HIV-infection. Clin Infect Dis. 2001;32:492-7. (Pubitemid 32173638)
13. Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166(15):1632-41. (Pubitemid 44232373)
14. Rosenthal E, Samon-Céron D, Lewden C, Bouteloup V, Pialoux G, Bonnet F, et al. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN 19). HIV Med. 2009;10(5):282-9.
15. Grebely J, Raffa JD, Meagher C, Duncan F, Genoway KA, Khara M, et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol. 2007;22(9):1519-25. (Pubitemid 47277379)
16. Grebely J, Genoway K, Khara M, Duncan F, Vilioen M, Elliott D, et al. Treatment uptakes and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy. 2007;18(5):437-43. (Pubitemid 47381422)
17. Schoeni-Affolter F, et al. Cohort Profile: The Swiss HIV Cohort Study. Int J Epidemiol. 2010;39:1179-89.
18. Schulthess K, Valkova K, Hauri D, Bachmann L, Steurer J, Seidenberg A. Hepatitis C infections in opioid-dependent patients (HepCOP1): a represenative survey on the state of care in the canton of Zurich. Schweiz Med Forum. 2008;8(Suppl 41):21.
19. Tuaillon E, Mondain AM, Meroueh F, Ottomani L, Picot MC, Nagot N, et al. Dried blood spot for hepatitis C virus serology and molecular testing. Hepatology. 2010;51:752-8.
20. Wong JB. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics. 2006;24(7):661-72. (Pubitemid 43998819)
21. Hornberger J, Torriani FJ, Dieterich DT, Bräu N, Sulkowski MS, Torres MR, et al. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. J Clin Virol. 2006;36(4):283-91. (Pubitemid 44066896)
22. Volk MI, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50:1750-5.
23. Sheerin IG, Green FT, Sellman JD. The costs of not treating hepatitis C virus infection in injecting drug users in New Zealand. Drug and Acohol Review. 2003;22:159-67. (Pubitemid 36814868)
24. Telser H, Müllhaupt B, Helbling B, Zweifel P. Kostenvergleich zwischen zwei Kombinationstherapien gegen Hepatitis C mit pegyliertem Interferonen und Ribavirin. Praxis. 2005;94(32):1207-14 (Available from: www.zora.uzh.ch/1201.)
25. BAG [homepage on the Internet]. Kosten der Transplantationsmedizin. [cited 2010 Jul 7]. Available from: www.bag.admin.ch/transplantation/ 00692/02582/03136/index.html?lang=de.
26. National Institute of Health. NIH Consensus Statement on management of hepatitis C: 2002. NIH Consens State Sci Statements. 2002;19:1-46.
27. Dhumeaux D, Marcellin P, Lerebours E. Treatment of hepatitis C. the French consensus. Gut. 2003;52:1784-7.
28. Overbeck K, Dufour JF, Müllhaupt B, Helbling B, Borovicka J, Malinverni R, et al. Impact of international consensus guidelines on antiviral therapy of chronic hepatitis C patients in Switzerland. Swiss Med Wkly. 2010;140(9-10):146-52.
29. Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Müllhaupt B, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 2009;51(4):655-66.
30. Matthews GV, Dore GJ. HIV and hepatitis C coinfection. J Gastroenterol Hepatol. 2008;23(7 Pt 1):1000-8. (Pubitemid 352019390)
31. Bruggmann P, Dampz M, Gerlach T, Kravecz L, Falcato L. Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study. Drug Alcohol Depend. 2010;110(1-2):167-71.
32. Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, Khalifa KE, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology. 2006;131(3):632-8. (Pubitemid 43374512)
33. Matthews GV, Helard M, Haber P, Yeung B, Marks P, Baker D, et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis. 2009;48:650-8.
34. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636-41. (Pubitemid 40585366)
35. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis: an update. Hepatology. 2009;49(4):1335-73.
36. Garfein RS, Vlahov D, Galai N, et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human t-lymphotropic viruses. Am J Public Health. 1996;86:655-61. (Pubitemid 26145477)
37. Thorpe LE, Quellet LJ, Levy JR, et al. Hepatitis C virus infection: prevalence, risk factors and prevention opportunities among young injection drug users in Chicago, 1997-1999. J Infect Dis. 2000;182:1588-94.
38. Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol. 2007;42:513-21. (Pubitemid 47190067)
39. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 1998;28(3):805-9. (Pubitemid 28405433)
40. Hézode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology. 2005;42(1):63-71. (Pubitemid 40911312)
41. Ishida JH, Peters MG, Jin C, Louie K, Tan V, Bacchetti P, et al. Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol. 2008;6(1):69-75. (Pubitemid 350309529)
42. Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol. 2008;23(4):512-20.
43. Thompson A, Patel K, Tillman H, McHutchison JG. Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. J Hepatol. 2009;50(1):184-94.
44. Forns S, Marcellin P, Ferenci P, Göser T, Nevens F, Carosi G, et al. Ontreatment response-guided therapy with telaprevir q8h or q12h combined with peginterferon alfa-2a or peginterferon alfa-2b and ribavirin in treatment-naive genotype 1 hepatitis C (study C208). J Hepatol. 2010;52(Suppl 1):S26.
45. Shehab TM, Sonnad SS, Lok AS. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. J Viral Hepat. 2001;8:377-83. (Pubitemid 34205892)
46. Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology. 2000;118:760-4. (Pubitemid 30171625)
47. Gonvers JJ, Heim MH, Cavassini M, Müllhaupt B, Genne D, Bernasconi E, et al. Treamtent of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study. Swiss Medical Wkly. 2010 (early online publication 14.6.2010).
48. Zinkernagel AS, von Wyl V, Ledergerber B, Rickenbach M, Furrer H, Battegay M, et al. Eligibility for and outcome of hepatitis treatment of HIV-coinfected individuals in clincial practice: the Swiss HIV cohort study. Antiviral Therapy. 2006;11:131-42.